News

 

At AseBio, we follow the latest news in the biotechnology sector and pass the highlights on to you. You can use the search engine to find news articles we’ve written, contributed by our members or from other stakeholders in the sector. And they are also organised into categories to help you find the topics you’re interested in easily.

Search engine
Fábrica multiproducto de Natac en Hervás
Natac ranks among the 20 companies with the highest return in Horizon Europe
Access to innovation
The company is the leading private entity in financing in Extremadura and in Cluster 6 - Food,…
Partners - Natac Group
Illumina TruPath Genome
Illumina launches TruPath Genome, setting a new standard in genomic insight
Healthcare
TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow. Data…
Partners - Illumina
Imagen generada por inteligencia artificial de una próstata
BCN HEALTH publishes a systematic review highlighting the substantial economic burden of prostate cancer
Healthcare
Despite advances in early detection, risk-adapted treatment, and precision oncology, the findings…
Partners - BCN Health
Científica trabajando con un ordenador
Genetics drives a new stage in precision preventive medicine
Healthcare · Personalized medicine
The integration of polygenic risk models based on genome-wide association studies (GWAS) enables…
Partners - ADNTRO GENETICS SL
Banner de la II Jornada sobre Biología Celular de Condalab
Catch up with Condalab: II Digital Cell Biology Conference
Healthcare · Advanced therapies
Condalab invites you to the second edition of our Digital Cell Biology Conference, a free online…
Partners - CONDALAB
Alfonso de Egaña, CEO de Molefy Pharma
#NewAseBioMember | “AseBio is a strategic opportunity to connect with the national and international biotechnology ecosystem”
Corporate
Meet Molefy Pharma, our new member. We spoke with Alfonso de Egaña, CEO.
AseBio - MOLEFY PHARMA
EDIFICIO ORYZON
ORYZON reports financial results and corporate update for quarter ended December 31st, 2025
Healthcare · Innovative drugs · Personalized medicine · Advanced therapies · Financing
Strong cash position at year-end 2025: $33.3 million (€28.4 million).
Partners - Oryzon Genomics
Científica observando muestras a través de un microscopio
Sequencing to diagnose earlier: how biotechnology can help short the rare diseases diagnostic odyssey
Healthcare · Rare diseases
In a context in which most of these pathologies have a genetic origin, tools such as whole genome…
Partners - Illumina
Cartel de la sesión de Genomcore en el Mobile World Congress 2026
Made of Genes Presents the "Athlete of the Future" at the Mobile World Congress 2026
Digitalization
The roundtable will address the use of artificial intelligence to integrate biomedical and…
Partners - GENOMCORE